{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:14:11Z","timestamp":1769159651429,"version":"3.49.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/mjt.0b013e31828232a3","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T21:56:33Z","timestamp":1363989393000},"page":"524-533","source":"Crossref","is-referenced-by-count":3,"title":["PTCL Therapies"],"prefix":"10.1097","volume":"20","author":[{"given":"Nadia","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210202","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killerT-cell lymphoma study: pathology findings and clinical outcomes.","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"R2-12-20210202","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":". ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"R3-12-20210202","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":". Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"R5-12-20210202","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":". Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe dEtude des Lymphomes de lAdulte.","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-12-20210202","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":". Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"R7-12-20210202","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":". Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"R8-12-20210202","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":". Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"R9-12-20210202","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":". Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.","volume":"29","author":"OConnor","year":"2011","journal-title":"J Clin Oncol"},{"key":"R11-12-20210202","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":". Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"R12-12-20210202","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":". Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"R13-12-20210202","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":". Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"R14-12-20210202","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":". A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"R15-12-20210202","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"F, Radford J, Relander T, et al.. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.","volume":"150","year":"2010","journal-title":"Br J Haematol"},{"key":"R16-12-20210202","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1200\/JCO.2010.29.7242","article-title":"Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.","volume":"28","author":"Suzuki","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-12-20210202","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":". Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"R18-12-20210202","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":". Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"R19-12-20210202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":". Phase II trial of denileukin diftitox for relapsedrefractory T-cell non-Hodgkin lymphoma.","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"R20-12-20210202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.V118.21.95.95","article-title":". Abstract Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of auror A kinase (AAK), in patients (pts) with aggressive B- an T-cell non-Hodgkin lymphoma (NHL).","volume":"118","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"R21-12-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/10428194.2011.618232","article-title":". Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.","volume":"53","author":"Wendtner","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R22-12-20210202","first-page":"1767","article-title":". Abstract Aplidin (Plitidepsin) activity in peripheral T-cell lymphoma (PTCL): final results.","volume":"116","author":"Ferme","year":"2010","journal-title":"Blood (ASH Annu Meet Abstracts)"},{"key":"R23-12-20210202","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":". Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood"},{"key":"R25-12-20210202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0609.2010.01540.x","article-title":". EORTC Lymphoma Group. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkins lymphoma-EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54).","volume":"86","author":"Aurer","year":"2011","journal-title":"Eur J Haematol"},{"key":"R27-12-20210202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":". Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R29-12-20210202","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1124\/mol.106.025569","article-title":". Plitidepsin cellular binding and Rac1JNK pathway activation depend on membrane cholesterol content.","volume":"70","author":"Suarez","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R30-12-20210202","first-page":"288","article-title":". Abstract phase III study of Dasatinib in relapsed or refractory Non-Hodgkins lymphoma (NHL).","volume":"116","author":"William","year":"2010","journal-title":"Blood (ASH Annu Meet Abstracts)"},{"key":"R31-12-20210202","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":". Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"R32-12-20210202","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":". Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"R33-12-20210202","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma.","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N Engl J Med"},{"key":"R35-12-20210202","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"F, Relander T, Lauritzsen GF, et al.. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"R36-12-20210202","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bmt.2008.332","article-title":". Hematopoietic SCT for peripheral T-cell lymphoma.","volume":"42","author":"Gutierrez","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R37-12-20210202","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":". Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkins lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31828232a3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:37:45Z","timestamp":1620963465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201309000-00012"}},"subtitle":["A Review of Treatment and Outline of Novel Therapies"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31828232a3","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}